Company News and Media Resources
January 9, 2023: First Patient Enrolled in the First-in-Human Clinical Trial of Novel AlucentNVS Technology
Alucent Biomedical Announces First Patient Enrolled in the First-in-Human Clinical Trial of Its Novel AlucentNVS Technology for Arteriovenous Fistula (AVF) in People with End Stage Renal Disease (ESRD) Press Release
April 2022: Alucent Biomedical Announces First Patient
First Patient Enrolled in First in Human Natural Vascular Scaffolding Clinical Trial Press Release
January 2021: Frontiers in Bioengineering & Biotechnology
Natural Vascular Scafolding Treatment PromotesOutward Remodeling during Arteriovenous Fistula Development in Rats. Read Article
January 2021: MedTech Strategist
Alucent Biomedical Re-Envisioning PAD Treatment with a Natural Vascular Scaffold. Read Article
Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market Press Release
Alucent Biomedical Announces $35 Million Series B Financing Press Release
Alucent Biomedical Announces First Patient Enrolled in Phase 1 Natural Vascular Scaffolding Clinical Trial Press Release
Alucent Biomedical Announces FDA Approval to Proceed with Natural Vascular Scaffolding Clinical Trial Press Release
Alucent Biomedical Announces Formation of Scientific Advisory Board Press Release
Proud to be part of the nations fastest growing Life Sciences Community.
By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving the lives of millions of patients.